Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer

Trial Profile

Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ULYSSES
  • Sponsors Advantagene
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 May 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 02 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top